Table 3.

Patient-related outcomes.

Patient-Related Efficacy (RCTs)
Morillo et al., 2015 [20]	No significant between-group differences were observed in any component of the primary outcome No significant differences between groups with new ECG abnormalities Treatment with BNZ did not reduce cardiac clinical progression
Torrico et al., 2018 [22]	ECG outcomes were similar across treatment groups, with no clinically significant increases in QTcF during treatment.
Patient-Related Efficacy (Observational Studies)
Antunes et al., 2016 [25]	No cardiac alterations were detected in the study population, regardless of group
Cardoso et al., 2018 [26]	14/493 (2.8%) of the treated group died during the 2-year follow-up; 100/1320 (7.6%) of the control group died during the 2-year follow-up (p ≤ 0.001) There was a reduction in well-established markers of CD severity, such as typical ECG abnormalities, high NT-proBNP levels or both. BNZ treatment reduced NT-proBNP levels.
Colantonio et al., 2016 [27]	After statistical adjustment treatment with BNZfor 60 days was not associated with less ECG abnormalities as compared to no treatment over a median follow-up of 8.6 years. The prevalence of ECGs with abnormalities was higher among children treated with BNZ compared with those not treated in all assessment periods following the baseline evaluation.
Fragata-Filho et al., 2016 [29]	20.92% of the treated patients developed ECG alterations. 3.19% of the untreated patients had worsening of ECG alterations. (p ≤ 0.0001) Death related to CD occurred in five participants with ECG alterations and in one with a normal ECG. (p = 0.001)
Schmidt et al., 2019 [31]	Those with even minimal wall motion abnormalities have poorer long-term outcomes. LV WMSI>1 was associated with a significantly increased primary outcome event rate and higher all-cause mortality (p ≤ 0.0001). BNZ had no significant effects on echocardiographic progression of CCC over 5.4 years.
Soverow, et al., 2019 [32]	Treated patients were less likely to have progression of their ECG disease (OR = 0.13, p < 0.001). Untreated patients had a higher likelihood of developing ECG abnormalities compared with their treated counterparts (56.7% vs. 11.9%, p ≤ 0.001).

ECG = Electrocardiogram, NT-proBNP = N-terminal of the prohormone brain natriuretic peptide, LV WMSI = Left ventricular wall motion score index, QTcF = QT interval/CubeRootRR (seconds).